Keyword: Third Rock Ventures
Armed with $65 million in series A funding, Celsius will sequence defined patient samples to identify the individual cells responsible for disease.
Armed with $58.5 million from Third Rock, Casma Therapeutics is working on autophagy-boosting treatments for various diseases.
Cedilla is targeting processes that transition cancer-driving proteins from a stable state to a state susceptible to degradation.
Constellation raised $100 million that will bankroll a cancer epigenetics asset through the clinic.
The drug discovery-stage company wants to tune the metabolism of immune cells to change their behavior.
John Davis, who headed early clinical development at Pfizer, joined Magenta Therapeutics.
Warp Drive has been working to live up to its name, speeding through development and deals.
Our panel discussed the meaning of good science and how different players can work together to leverage their respective strengths.
PanOptica plans to start trialling the small molecule anti-vascular endothelial growth factor eye drop early next year.